Patterns of long-term ADHD medication use in Australian children.
Adolescent
Atomoxetine Hydrochloride
/ therapeutic use
Attention Deficit Disorder with Hyperactivity
/ drug therapy
Australia
/ epidemiology
Central Nervous System Stimulants
/ therapeutic use
Child
Child, Preschool
Dextroamphetamine
/ therapeutic use
Drug Prescriptions
/ statistics & numerical data
Female
Humans
Longitudinal Studies
Male
Medication Adherence
/ statistics & numerical data
Methylphenidate
/ therapeutic use
Sex Distribution
Social Class
adherence
attention-deficit/hyperactivity disorder
medication
Journal
Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
31
07
2019
revised:
11
12
2019
accepted:
12
12
2019
pubmed:
16
1
2020
medline:
21
10
2020
entrez:
16
1
2020
Statut:
ppublish
Résumé
Adherence to attention-deficit/hyperactivity disorder (ADHD) medication treatment is often suboptimal. This can compromise patient outcomes. We aimed to describe the patterns of ADHD medication use in Australian children, and characteristics associated with patterns of use. Dispensing data were analysed for all redeemed prescriptions of methylphenidate, dexamphetamine and atomoxetine between May 2002 and March 2015 from waves 1 to 6 of the Longitudinal Study of Australian Children (n=4634, age 4-5 years at wave 1). Medication coverage was defined as the proportion of time between the first and the last redeemed prescriptions in which the child was taking medication. Associations between predictor variables (child sex, ADHD symptom severity, age at first prescription, family socioeconomic status (SES), single parent status, parent education and parent mental health) and medication coverage were examined using regression analyses. 166 (3.6%) children had ever redeemed a prescription for an ADHD medication. Boys had higher odds of having taken ADHD medication than girls (OR=3.9; 95% CI 2.7 to 5.7). The mean medication coverage was 59.8%. Medication coverage was lower in children from families of lower SES (β=4.0; 95% CI 0.2 to 7.8, p=0.04). Medication coverage was relatively high in the first year of prescription, then decreased progressively, only increasing again after 5 or 6 years of treatment. Children with ADHD from socially disadvantaged families were less likely to receive medication consistently. Prescribers need to continue to support families over many years to ensure medication is used consistently for children with ADHD.
Identifiants
pubmed: 31937570
pii: archdischild-2019-317997
doi: 10.1136/archdischild-2019-317997
doi:
Substances chimiques
Central Nervous System Stimulants
0
Methylphenidate
207ZZ9QZ49
Atomoxetine Hydrochloride
57WVB6I2W0
Dextroamphetamine
TZ47U051FI
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
593-597Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: DC reports grants and personal fees from Shire, personal fees from Eli Lilly, personal fees from Medice, personal fees from Novartis, personal fees from Oxford University Press, grants from Vifor, personal fees from Servier.